Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
From fungus to virus: terbinafine in chronic hepatitis B (Phase 2a)
2019-003419-68Phase 2Active
- Sponsor
- Academic Medical Center
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of Terbinafine in hepatitis B (HBV), sponsored by Academic Medical Center. Primary endpoint: HBx-mediated cccDNA transcription inhibition (terbinafine monotherapy and add-on to tenofovir). Started Mar 2020; status: active.
02
Drugs
Terbinafine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2019-003419-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003419-68.